Olthuis Janine V, Watt Margo C, Bailey Kristen, Hayden Jill A, Stewart Sherry H
Department of Psychology and Neuroscience, Dalhousie University, 1355 Oxford Street, Halifax, NS, Canada, B3H 4J1.
Cochrane Database Syst Rev. 2016 Mar 12;3(3):CD011565. doi: 10.1002/14651858.CD011565.pub2.
Cognitive behavioural therapy (CBT) is an evidence-based treatment for anxiety disorders. Many people have difficulty accessing treatment, due to a variety of obstacles. Researchers have therefore explored the possibility of using the Internet to deliver CBT; it is important to ensure the decision to promote such treatment is grounded in high quality evidence.
To assess the effects of therapist-supported Internet CBT (ICBT) on remission of anxiety disorder diagnosis and reduction of anxiety symptoms in adults as compared to waiting list control, unguided CBT, or face-to-face CBT. Effects of treatment on quality of life and patient satisfaction with the intervention were also assessed.
We searched the Cochrane Depression, Anxiety and Neurosis Review Group Specialised Register (CCDANCTR) to 16 March 2015. The CCDANCTR includes relevant randomised controlled trials from MEDLINE, EMBASE, PsycINFO and CENTRAL. We also searched online clinical trial registries and reference lists of included studies. We contacted authors to locate additional trials.
Each identified study was independently assessed for inclusion by two authors. To be included, studies had to be randomised controlled trials of therapist-supported ICBT compared to a waiting list, attention, information, or online discussion group; unguided CBT (that is, self-help); or face-to-face CBT. We included studies that treated adults with an anxiety disorder (panic disorder, agoraphobia, social phobia, post-traumatic stress disorder, acute stress disorder, generalized anxiety disorder, obsessive compulsive disorder, and specific phobia) defined according to the Diagnostic and Statistical Manual of Mental Disorders III, III-R, IV, IV-TR or the International Classification of Disesases 9 or 10.
Two authors independently assessed the risk of bias of included studies and judged overall study quality. We used data from intention-to-treat analyses wherever possible. We assessed treatment effect for the dichotomous outcome of clinically important improvement in anxiety using a risk ratio (RR) with 95% confidence interval (CI). For disorder-specific and general anxiety symptom measures and quality of life we assessed continuous scores using standardized mean differences (SMD). We examined statistical heterogeneity using the I(2) statistic.
We screened 1736 citations and selected 38 studies (3214 participants) for inclusion. The studies examined social phobia (11 trials), panic disorder with or without agoraphobia (8 trials), generalized anxiety disorder (5 trials), post-traumatic stress disorder (2 trials), obsessive compulsive disorder (2 trials), and specific phobia (2 trials). Eight remaining studies included a range of anxiety disorder diagnoses. Studies were conducted in Sweden (18 trials), Australia (14 trials), Switzerland (3 trials), the Netherlands (2 trials), and the USA (1 trial) and investigated a variety of ICBT protocols. Three primary comparisons were identified, therapist-supported ICBT versus waiting list control, therapist-supported versus unguided ICBT, and therapist-supported ICBT versus face-to-face CBT.Low quality evidence from 11 studies (866 participants) contributed to a pooled risk ratio (RR) of 3.75 (95% CI 2.51 to 5.60; I(2) = 50%) for clinically important improvement in anxiety at post-treatment, favouring therapist-supported ICBT over a waiting list, attention, information, or online discussion group only. The SMD for disorder-specific symptoms at post-treatment (28 studies, 2147 participants; SMD -1.06, 95% CI -1.29 to -0.82; I(2) = 83%) and general anxiety symptoms at post-treatment (19 studies, 1496 participants; SMD -0.75, 95% CI -0.98 to -0.52; I(2) = 78%) favoured therapist-supported ICBT; the quality of the evidence for both outcomes was low.One study compared unguided CBT to therapist-supported ICBT for clinically important improvement in anxiety at post-treatment, showing no difference in outcome between treatments (54 participants; very low quality evidence). At post-treatment there were no clear differences between unguided CBT and therapist-supported ICBT for disorder-specific anxiety symptoms (5 studies, 312 participants; SMD -0.22, 95% CI -0.56 to 0.13; I(2) = 58%; very low quality evidence) or general anxiety symptoms (2 studies, 138 participants; SMD 0.28, 95% CI -2.21 to 2.78; I(2) = 0%; very low quality evidence).Compared to face-to-face CBT, therapist-supported ICBT showed no significant differences in clinically important improvement in anxiety at post-treatment (4 studies, 365 participants; RR 1.09, 95% CI 0.89 to 1.34; I(2) = 0%; low quality evidence). There were also no clear differences between face-to-face and therapist supported ICBT for disorder-specific anxiety symptoms at post-treatment (7 studies, 450 participants; SMD 0.06, 95% CI -0.25 to 0.37; I(2) = 60%; low quality evidence) or general anxiety symptoms at post-treatment (5 studies, 317 participants; SMD 0.17, 95% CI -0.35 to 0.69; I(2) = 78%; low quality evidence).Overall, risk of bias in included studies was low or unclear for most domains. However, due to the nature of psychosocial intervention trials, blinding of participants and personnel, and outcome assessment tended to have a high risk of bias. Heterogeneity across a number of the meta-analyses was substantial, some was explained by type of anxiety disorder or may be meta-analytic measurement artefact due to combining many assessment measures. Adverse events were rarely reported.
AUTHORS' CONCLUSIONS: Therapist-supported ICBT appears to be an efficacious treatment for anxiety in adults. The evidence comparing therapist-supported ICBT to waiting list, attention, information, or online discussion group only control was low to moderate quality, the evidence comparing therapist-supported ICBT to unguided ICBT was very low quality, and comparisons of therapist-supported ICBT to face-to-face CBT were low quality. Further research is needed to better define and measure any potential harms resulting from treatment. These findings suggest that therapist-supported ICBT is more efficacious than a waiting list, attention, information, or online discussion group only control, and that there may not be a significant difference in outcome between unguided CBT and therapist-supported ICBT; however, this latter finding must be interpreted with caution due to imprecision. The evidence suggests that therapist-supported ICBT may not be significantly different from face-to-face CBT in reducing anxiety. Future research should explore heterogeneity among studies which is reducing the quality of the evidence body, involve equivalence trials comparing ICBT and face-to-face CBT, examine the importance of the role of the therapist in ICBT, and include effectiveness trials of ICBT in real-world settings. A timely update to this review is needed given the fast pace of this area of research.
认知行为疗法(CBT)是一种针对焦虑症的循证治疗方法。由于各种障碍,许多人难以获得治疗。因此,研究人员探索了利用互联网提供CBT的可能性;确保推广这种治疗方法的决策基于高质量证据非常重要。
评估与等待名单对照、无指导的CBT或面对面CBT相比,有治疗师支持的互联网CBT(ICBT)对成人焦虑症诊断缓解和焦虑症状减轻的效果。还评估了治疗对生活质量和患者对干预满意度的影响。
我们检索了截至2015年3月16日的Cochrane抑郁、焦虑和神经症综述小组专业注册库(CCDANCTR)。CCDANCTR包括来自MEDLINE、EMBASE、PsycINFO和CENTRAL的相关随机对照试验。我们还检索了在线临床试验注册库和纳入研究的参考文献列表。我们联系了作者以查找其他试验。
每项纳入的研究由两名作者独立评估是否符合纳入标准。要纳入研究,必须是将有治疗师支持的ICBT与等待名单、注意力、信息或在线讨论组进行比较的随机对照试验;无指导的CBT(即自助);或面对面CBT。我们纳入了根据《精神疾病诊断与统计手册》第三版、第三版修订本、第四版、第四版修订本或《国际疾病分类》第九版或第十版定义的患有焦虑症(惊恐障碍、广场恐惧症、社交恐惧症、创伤后应激障碍、急性应激障碍、广泛性焦虑症、强迫症和特定恐惧症)的成人的研究。
两名作者独立评估纳入研究的偏倚风险并判断总体研究质量。我们尽可能使用意向性分析的数据。我们使用风险比(RR)及95%置信区间(CI)评估焦虑症临床重要改善这一二分结果的治疗效果。对于特定障碍和一般焦虑症状测量以及生活质量,我们使用标准化均数差(SMD)评估连续得分。我们使用I²统计量检查统计异质性。
我们筛选了1736条引文,选择了38项研究(3214名参与者)纳入。这些研究考察了社交恐惧症(11项试验)、伴或不伴广场恐惧症的惊恐障碍(8项试验)、广泛性焦虑症(5项试验)、创伤后应激障碍(2项试验)、强迫症(2项试验)和特定恐惧症(2项试验)。其余8项研究纳入了一系列焦虑症诊断。研究在瑞典(18项试验)、澳大利亚(14项试验)、瑞士(3项试验)、荷兰(2项试验)和美国(1项试验)进行,并研究了多种ICBT方案。确定了三项主要比较,有治疗师支持的ICBT与等待名单对照、有治疗师支持的与无指导的ICBT、有治疗师支持的ICBT与面对面CBT。11项研究(866名参与者)的低质量证据得出治疗后焦虑症临床重要改善的合并风险比(RR)为3.75(95%CI 2.51至5.60;I² = 50%),表明有治疗师支持的ICBT优于仅等待名单、注意力、信息或在线讨论组。治疗后特定障碍症状的SMD(28项研究,2147名参与者;SMD -1.06,95%CI -1.29至 -0.82;I² = 83%)和治疗后一般焦虑症状的SMD(19项研究,1496名参与者;SMD -0.75,95%CI -0.98至 -0.52;I² = 78%)支持有治疗师支持的ICBT;这两个结果的证据质量都很低。一项研究比较了无指导的CBT和有治疗师支持的ICBT在治疗后焦虑症临床重要改善方面的情况,结果显示治疗效果无差异(54名参与者;极低质量证据)。治疗后,无指导的CBT和有治疗师支持的ICBT在特定障碍焦虑症状方面无明显差异(5项研究,312名参与者;SMD -0.22,95%CI -0.56至0.13;I² = 58%;极低质量证据)或一般焦虑症状方面也无明显差异(2项研究,138名参与者;SMD 0.28,95%CI -2.21至2.78;I² = 0%;极低质量证据)。与面对面CBT相比,有治疗师支持的ICBT在治疗后焦虑症临床重要改善方面无显著差异(4项研究,365名参与者;RR 1.09,95%CI 0.89至1.34;I² = 0%;低质量证据)。治疗后,面对面和有治疗师支持的ICBT在特定障碍焦虑症状方面也无明显差异(7项研究,450名参与者;SMD 0.06,95%CI -0.25至0.37;I² = 60%;低质量证据)或治疗后一般焦虑症状方面也无明显差异(5项研究,317名参与者;SMD 0.17,95%CI -0.35至0.69;I² = 78%;低质量证据)。总体而言,纳入研究中大多数领域的偏倚风险较低或不明确。然而,由于心理社会干预试验性质的原因,参与者、人员的盲法以及结果评估往往存在较高的偏倚风险。多个荟萃分析中的异质性很大,一些是由焦虑症类型解释的,或者可能是由于合并许多评估措施导致的荟萃分析测量假象。不良事件很少被报告。
有治疗师支持的ICBT似乎是成人焦虑症的一种有效治疗方法。将有治疗师支持的ICBT与仅等待名单、注意力、信息或在线讨论组进行比较的证据质量低至中等,将有治疗师支持的ICBT与无指导的ICBT进行比较的证据质量极低,将有治疗师支持的ICBT与面对面CBT进行比较的证据质量低。需要进一步研究以更好地定义和测量治疗可能产生的任何潜在危害。这些发现表明,有治疗师支持的ICBT比仅等待名单、注意力、信息或在线讨论组更有效,并且无指导的CBT和有治疗师支持的ICBT在结果上可能没有显著差异;然而,由于不精确性,后一发现必须谨慎解释。证据表明,有治疗师支持的ICBT在减轻焦虑方面可能与面对面CBT没有显著差异。未来的研究应探索降低证据质量的研究间异质性,开展比较ICBT和面对面CBT的等效性试验,研究治疗师在ICBT中的作用的重要性,并纳入ICBT在现实环境中的有效性试验。鉴于该研究领域的快速发展,需要及时更新本综述。